Tildrakizumab - Almirall/Sun Pharmaceutical Industries
At a glance
- Drug Originator Schering-Plough
- Drug Licenced by Almirall S.A.; China Medical System; Hikma Pharmaceuticals; Sun Pharmaceutical Industries
- Drug Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-23 subunit p19 inhibitors; T lymphocyte stimulants
- USA Patent Applicants SUN PHARMA GLOBAL
- USA Patents 4
- BLAs 1
- International Patents 54

Disclaimer